Median Technologies and Tempus Partner to Expand Lung Cancer Screening in the U.S.

On February 12, 2026, Median Technologies announced a collaboration with Tempus AI to distribute its eyonis® LCS software across the United States. This partnership follows eyonis® LCS's recent FDA 510(k) clearance. The collaboration aims to integrate advanced lung cancer detection technology into clinical workflows via the Tempus Pixel platform.

eyonis® LCS is a high-performance AI-enabled software designed for early detection of lung cancer, boasting a sensitivity of 93.3% and a specificity of 92.4%. As part of the agreement, Tempus AI will facilitate distribution and integration of eyonis® LCS, targeting America's 14.5 million eligible lung cancer screening candidates.

Revenues from eyonis® LCS will be shared between Median and Tempus. The partnership builds upon the NT-APC 1508 reimbursement pathway and seeks to enhance the standard of care in the U.S. Additionally, the rollout in Europe is anticipated, pending CE marking in Q2 2026.